buthionine sulfoximine has been researched along with Cardiac Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelhamid, G; El-Kadi, AO | 1 |
| Wang, X; Xu, T; Zhang, J | 1 |
2 other study(ies) available for buthionine sulfoximine and Cardiac Failure
| Article | Year |
|---|---|
Buthionine sulfoximine, an inhibitor of glutathione biosynthesis, induces expression of soluble epoxide hydrolase and markers of cellular hypertrophy in a rat cardiomyoblast cell line: roles of the NF-κB and MAPK signaling pathways.
Topics: Animals; Antioxidants; Atrial Natriuretic Factor; Butadienes; Buthionine Sulfoximine; Cardiomegaly; Cell Line; Cell Survival; Enzyme Activation; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation; Glutathione; Heart Failure; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Myoblasts, Cardiac; Natriuretic Peptide, Brain; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Nitriles; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proline; Rats; RNA, Messenger; Thiocarbamates; Transcription Factor RelA; Up-Regulation | 2015 |
Cyclophosphamide-evoked heart failure involves pronounced co-suppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level.
Topics: Animals; Antineoplastic Agents, Alkylating; Buthionine Sulfoximine; Cyclophosphamide; Cytoplasm; Dose-Response Relationship, Drug; Glutathione; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Myocardium; Sulfhydryl Compounds; Thioredoxin-Disulfide Reductase | 2009 |